{"bill": {"#text": "\n\t", "form": {"current-chamber": {"#tail": "\n\t\t", "#text": "IN THE HOUSE OF REPRESENTATIVES"}, "#text": "\n\t\t", "congress": {"#tail": "\n\t\t", "#text": "113th CONGRESS"}, "#tail": "\n\t", "legis-num": {"#tail": "\n\t\t", "#text": "H. R. 4299"}, "official-title": {"#tail": "\n\t", "#text": "To amend the Controlled Substances Act with respect to drug scheduling recommendations by the\n\t\t\t Secretary of Health and Human Services, and with respect to registration\n\t\t\t of manufacturers and distributors seeking to conduct clinical testing."}, "session": {"#tail": "\n\t\t", "#text": "2d Session"}, "distribution-code": {"#tail": "\n\t\t", "@display": "yes", "#text": "I"}, "action": {"action-date": {"#tail": "\n\t\t\t", "@date": "20140326", "#text": "March 26, 2014"}, "#tail": "\n\t\t", "action-desc": {"#tail": "\n\t\t", "#text": "\n        ", "committee-name": [{"#tail": ", and in addition to the ", "@committee-id": "HIF00", "#text": "Committee on Energy and Commerce"}, {"#tail": ", for a period to be subsequently determined by the Speaker, in each case for consideration of such\n\t\t\t provisions as fall within the jurisdiction of the committee concerned", "@committee-id": "HJU00", "#text": "Committee on the Judiciary"}], "sponsor": {"#tail": " (for himself and ", "#text": "Mr. Pitts", "@name-id": "P000373"}, "cosponsor": {"#tail": ") introduced the following bill; which was referred to the ", "#text": "Mr. Pallone", "@name-id": "P000034"}}, "#text": "\n\t\t\t"}, "legis-type": {"#tail": "\n\t\t", "#text": "A BILL"}}, "@bill-stage": "Introduced-in-House", "@bill-type": "olc", "@dms-id": "H4C41E6F7E04B47078D23FC4CA2D6C3A0", "@public-private": "public", "legis-body": {"#tail": "\n", "@style": "OLC", "section": [{"@section-type": "section-one", "#tail": "\n    ", "text": {"#tail": "\n\t\t", "quote": {"short-title": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "act", "#text": "Improving Regulatory Transparency for New Medical Therapies Act", "@value": "Improving Regulatory Transparency for New Medical Therapies Act", "@proposed": "true"}, "#text": "\n            "}, "#tail": ".", "#text": "\n          "}, "#text": "This Act may be cited as the ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n      ", "#text": "Short title"}, "#text": "\n      ", "@id": "H50C178AFA00F4508B6D6A6560D7B53ED"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " the following:", "@entity-type": "act", "#text": "subsection (h)", "@value": "Controlled Substances Act/s:201/ss:h"}, "#text": "\n        ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by inserting after\n\t\t\t ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 201 of the Controlled Substances Act", "@value": "Controlled Substances Act/s:201"}, "@entity-type": "law-citation", "#text": "\n          ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n        ", "@entity-type": "uscode", "#text": "21 U.S.C. 811", "@value": "usc/21/811"}, "@parsable-cite": "usc/21/811", "#text": "\n          ", "@legal-doc": "usc"}}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "2."}, "header": {"#tail": "\n      ", "#text": "Scheduling of substances included in new FDA-approved drugs"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n      ", "#text": "."}, "#tail": "\n\t\t", "subsection": {"#tail": "\n        ", "text": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " to add a drug or substance that has\n\t\t\t never been marketed in the United States to a schedule under this title,\n\t\t\t the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " shall, without regard to the findings required by\n\t\t\t ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": " or ", "@entity-type": "act", "#text": "subsection (a) of this section", "@value": "Controlled Substances Act/s:201/ss:a"}, {"#tail": ", issue an interim final\n\t\t\t rule, under the exception for good cause described in ", "@entity-type": "act", "#text": "section 202(b)", "@value": "Controlled Substances Act/s:202/ss:b"}, {"#tail": ", placing the drug or\n\t\t\t substance into the schedule recommended by the ", "@entity-type": "uscode", "#text": "subparagraph (B) of\n\t\t\t ", "external-xref": {"#tail": " of title 5, United States Code", "@parsable-cite": "usc/5/553", "#text": "section 553(b)", "@legal-doc": "usc"}, "@value": "usc/5/553/b//B"}, {"#tail": ". The interim\n\t\t\t final rule shall be made immediately effective under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ".", "@entity-type": "uscode", "#text": "section 553(d)(3) of\n\t\t\t title 5, United States Code", "@value": "usc/5/553/d/3"}], "#text": "Within 45 days of receiving a recommendation from the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(i)"}, "@id": "H956A198CA01D4E9699386C70F5CD2DFE", "#text": "\n          "}, "#text": "\n\t\t\t\t", "@id": "HF92623B6E0604C849F1CB660CB9CF7B9"}, "#text": "\n      ", "@id": "H99F61C2A5E3C4A798F9F2149DD18DFE0"}, {"#tail": "\n  ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " the following:", "@entity-type": "act", "#text": "subsection (g)", "@value": "Controlled Substances Act/s:302/ss:g"}, "#text": "\n        ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by inserting after\n\t\t\t ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 302 of the Controlled Substances Act", "@value": "Controlled Substances Act/s:302"}, "@entity-type": "law-citation", "#text": "\n          ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n        ", "@entity-type": "uscode", "#text": "21 U.S.C. 822", "@value": "usc/21/822"}, "@parsable-cite": "usc/21/822", "#text": "\n          ", "@legal-doc": "usc"}}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "3."}, "header": {"#tail": "\n      ", "#text": "Enhancing new drug development"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n      ", "#text": "."}, "#tail": "\n\t\t", "subsection": {"#tail": "\n        ", "#text": "\n          ", "enum": {"#tail": "\n\t\t\t\t\t", "#text": "(h)"}, "@id": "HF2A73ADF44F54B218F20AFB7008F5C92", "paragraph": [{"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "section 505(i) of the Federal\n\t\t\t Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:i"}, "#text": "A person who submits an application for registration to manufacture or distribute a controlled\n\t\t\t substance in accordance with this section may indicate on the registration\n\t\t\t application that the substance will be used only in connection with\n\t\t\t clinical trials of a drug in accordance with "}, "enum": {"#tail": "\n            ", "#text": "(1)"}, "@display-inline": "yes-display-inline", "#text": "\n            ", "@id": "HDD63E7052F8E473FA3B96EE446648EDB", "@commented": "no"}, {"@indent": "up1", "#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", the ", "@entity-type": "act", "#text": "section\n\t\t\t 505(i) of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:i"}, {"#tail": "\n\t\t\t shall\u2014", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}], "#text": "When an application for registration to manufacture or distribute a controlled substance includes\n\t\t\t an indication that the controlled substance will be used only in\n\t\t\t connection with clinical trials of a drug in accordance with "}, "enum": {"#tail": "\n            ", "#text": "(2)"}, "#text": "\n            ", "@id": "H651AEA7933CD43319C7BA55231DE9DD9", "subparagraph": [{"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "#text": "make a final decision on the application for registration within 180 days; or"}, "enum": {"#tail": "\n              ", "#text": "(A)"}, "@id": "H3942D2C99E324569A4794CC20039393A", "#text": "\n              "}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "provide notice to the applicant in writing of\u2014"}, "enum": {"#tail": "\n              ", "#text": "(B)"}, "clause": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "the outstanding issues that must be resolved in order to reach a final decision on the application;\n\t\t\t and"}, "enum": {"#tail": "\n                ", "#text": "(i)"}, "@id": "H41FD75B83D884EF2A12A07311FF5C866", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "the estimated date on which a final decision on the application will be made."}, "enum": {"#tail": "\n                ", "#text": "(ii)"}, "@id": "H1050D99947004C93B7AE35C5AF3884B1", "#text": "\n                "}], "#text": "\n              ", "@id": "HBC6ACE82E98E4FE39214CD01729720E1"}]}]}, "#text": "\n\t\t\t\t", "@id": "HC162F4D7FAF94B0AA24C8186367E9B1A"}, "#text": "\n      ", "@id": "H3DB6FFA0B1A74E0EB1E5F0DD55D30F01"}], "#text": "\n\t\t", "@id": "H3D7856030F154CAB9CA7B3EE1120FC3D"}, "metadata": {"#tail": "\n", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n", "#text": "2014-03-26"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n", "#text": "EN"}, "#tail": "\n", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n", "#text": "113 HR 4299 IH: Improving Regulatory Transparency for New Medical Therapies Act"}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n", "#text": "U.S. House of Representatives"}, "#text": "\n"}, "#text": "\n"}}}